Navigation Links
Researchers discover brain tumor's 'grow-or-go' switch
Date:3/11/2010

COLUMBUS, Ohio Cancer cells in rapidly growing brain tumors must adjust to periods of low energy or die. When energy levels are high, tumor cells grow and proliferate. When levels are low, the cells grow less and migrate more.

Researchers at the Ohio State University Comprehensive Cancer Center-Arthur G. James Cancer Hospital and Richard J. Solove Research Institute have discovered the switch responsible for this grow-or-go behavior.

Their study shows that a molecule called miR-451 coordinates the change, and that the change is accompanied by slower cell proliferation and an increase in cell migration.

This behavior was closely linked to the cancer's ability to invade and spread. For this reason the molecule might serve as a biomarker to predict how long patients with the brain tumor glioblastoma multiforme will survive and may serve as a target to develop drugs to fight these tumors.

The researchers found that glioblastoma cells shift from their typical means of metabolizing glucose a sugar brought by the bloodstream and usually used for energy to an alternate means that consumes resources within the cell.

The findings are published in the March 12 issue of the journal Molecular Cell. "

Our study reveals how brain tumor cells adapt to their surroundings and survive conditions that might fatally starve them of energy," says co-author Dr. E. Antonio Chiocca, professor and chair of Neurological Surgery at Ohio State. "We have discovered that glioblastoma cells use miR451 to sense the availability of a nutrient glucose.

"Levels of miR-451 directly shut down the engine of the tumor cell if there in no glucose or rev it up if there is lots of glucose. This important insight suggests that this molecule might be useful as a biomarker to predict a glioblastoma patient's prognosis, and that it might be used as a target to develop drugs to fight these tumors."

About 10,000 new cases of glioblastoma multiforme occur annually in the United States. The tumors are highly invasive, which makes them difficult to remove surgically, and respond poorly to radiation therapy and chemotherapy.

Average survival is 14 months after diagnosis.

MiR-451 belongs to a class of molecules called microRNA, which play a key role in regulating the levels of proteins that cells make. Changes in levels of these molecules are a feature of many cancers, the researchers say.

"The change in miR-451 expression enabled the cells to survive periods of stress caused by low glucose, and it causes them to move, perhaps enabling them to find a better glucose supply," says principal investigator Sean Lawler, assistant professor of neurological surgery.

"The migration of cancer cells from the primary tumor, either as single cells or as chains of cells, into the surrounding brain is a real problem with these tumors. By targeting miR-451, we might limit the tumor's spread and extend a patient's life."

For this study, Lawler, Chiocca, Jakub Godlewski, the postdoctoral fellow who was the first author of the study, and their colleagues first compared microRNA levels in migrating and nonmigrating human glioblastoma multiforme cells. The analysis suggested an important role for miR-451.

Experiments with living cells showed that high levels of glucose correlated with high levels of the molecule, and that this promotes a high rate of tumor-cell proliferation. Low glucose levels, on the other hand, slowed cell proliferation and increased cell migration.

Furthermore, when the researchers boosted levels of the molecule in migrating cells, it slowed migration 60 percent, and, after 72 hours, nearly doubled the rate of cell proliferation compared with controls.

Most exciting, when they forced an increase in miR-451 levels, the cells quickly died, suggesting a possible role in therapy.

Analyses of patient tumors showed that three of five had elevated levels of the molecule. Finally, the researchers compared the survival in 16 patients with high miR-451 and 23 patients with low levels. Those with high levels of the molecule had an average survival of about 280 days while those with low levels lived an average of about 480 days.

"This suggests that molecule may be a useful prognostic marker," Chiocca says.


'/>"/>

Contact: Darrell E. Ward
Darrell.Ward@osumc.edu
614-293-3737
Ohio State University Medical Center
Source:Eurekalert

Related medicine news :

1. Exposure to BPA may cause permanent fertility defects, Yale researchers find
2. MRI finds tumors in second breast of women diagnosed with cancer in one breast, Mayo researchers say
3. Researchers find further evidence linking Epstein-Barr virus and risk of multiple sclerosis
4. Learning keeps brain healthy, UCI researchers find
5. Sea Squirt Helps Researchers Test New Alzheimers Drug
6. UMass Lowell researchers findings suggest new ways to diagnose and treat Alzheimers
7. Researchers find that sociodemographic characteristics are related to a patients willingness to participate in cancer screenings
8. Veterans Affairs Researchers Induce a New Transmissible Prion Disease
9. New Building at University of Michigan Health System Expands Eye Care, Unites Diabetes Researchers
10. Multiple sclerosis, Italian researchers discover a possible onset mechanism for the disease
11. HIV drug that protects a fetus should be avoided for one year after childbirth, researchers say
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... CA (PRWEB) , ... February 24, 2017 , ... ... for qualifying into the Senior International Elite division on February 12th. Ms. ... Around divisions at the elite qualifier competition held in Las Vegas, Nevada. Frida ...
(Date:2/23/2017)... ... 2017 , ... The 89th Academy Awards will be celebrated this weekend, which ... Center Bunkum Award. We invite you to enjoy our 11th annual tongue-in-cheek “salute” to ... the Center for American Progress (CAP), for its report, Lessons From State Performance on ...
(Date:2/23/2017)... ... ... Los Angeles-based weight loss surgeon Michael Feiz, M.D., F.AC.S. will be appearing ... which will begin airing on February 24, 2017. The show chronicles the weight loss ... television series, “Here Comes Honey Boo Boo.” The earlier series from TLC lasted for ...
(Date:2/23/2017)... Los Angeles, California (PRWEB) , ... February 23, ... ... for Global Sports Development will host a diverse symposium on “Doping ... School of Law and Sheppard Mullin Richter & Hampton LLP. The symposium will ...
(Date:2/23/2017)... ... February 23, 2017 , ... ... it will soon begin franchising throughout the U.S. starting this spring. Current Meditation ... the practice of meditation mainstream. Current Meditation will be the first meditation concept ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 23, 2017  Directors from Pharma To Market ... companies have joined forces, resulting in the founding of Pharma To ... Pharma To Market are pleased to announce their expansion into ... in Singapore . The company are delighted to ... Co-Director of the Singapore based entity. Joelle ...
(Date:2/24/2017)... , Feb. 23, 2017 Non-alcoholic ... on the various drugs being developed for ... all the drugs that are in various ... The pipeline focuses on novel pharmacologic drugs ... stem cell therapies, recombinant proteins and RNA-based ...
(Date:2/24/2017)... STOCKHOLM , Feb 24, 2017 ... Nomination Committee,s proposal for a new Board of Directors ... Meeting. The 2016-2017 Nomination Committee comprises representatives of the ... third quarter of 2016 who have accepted a seat ... Board. The composition of the 2016-2017 Nomination Committee was ...
Breaking Medicine Technology: